Account
Inquiry
XCE tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist developed for type 2 diabetes research. It demonstrates superior efficacy in glucose control and weight loss compared to other agonists like dulaglutide. The molecular structure of XCE tirzepatide includes a PEG-modified lysine side chain, enhancing water solubility and functional performance in research applications.
In clinical studies, XCE tirzepatide has shown significant weight loss results in overweight subjects, with average reductions of 15% to 20.9% over 72 weeks depending on dosage. It is designed for once-weekly administration and has received FDA Fast Track designation for obesity-related research, highlighting its potential in metabolic studies.
XCE tirzepatide is supplied as a white powder with high purity (99.9%), ensuring reliability for laboratory and research purposes. It is available in vials of 10mg or 20mg, packaged securely to maintain stability. Proper storage guidelines include keeping the peptide in a cold, dry, and dark environment, avoiding repeated freeze-thaw cycles, light exposure, and long-term storage in solution to preserve integrity.
This product is intended for research use only and not for human consumption. Researchers can customize orders for bulk quantities or specific packaging requirements, supported by factory-direct pricing and quality assurance.
